Los Angeles, California 90048

  • Thrombosis


Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis. Some of these patients will require surgery while on dual antiplatelet therapy. This poses a challenge because being on Plavix is associated with higher risks of perioperative bleeding, but stopping Plavix puts patients at increased risk for in-stent thrombosis. Currently, the ACC/AHA guidelines recommend discontinuation of Plavix five days prior to surgery to prevent bleeding complications. However, there are no universal recommendations for preventing in-stent thrombosis. Some experts recommend the use glycoprotein IIb/IIIa inhibitors (short-acting antiplatelet agents) as "bridging therapy" during the high-risk perioperative period. Although these agents should be beneficial based on theory, there is currently no published data on their effectiveness for this purpose. The current study proposes to evaluate the value of Aggrastat (a short-acting intravenous platelet glycoprotein IIb/IIIa inhibitor) in decreasing the risk of in-stent thrombosis without increasing the risk of perioperative bleeding.

Study summary:

A. D/C clopidogrel 5 days prior to surgery B. Continue ASA (Increase dose to 325 mg until prohibitive bleeding risk) C. Check baseline IIb/IIIa and P2Y12 via the Verify Now device prior to initiating tirofiban D. Start Tirofiban 2 days prior to the procedure (Patient MUST be on a monitored bed) - Load Tirofiban ONLY if P2Y12 (Verify Now Assay) platelet inhibition is < 20% OTHERWISE initiate only the continuous infusion dose - Creatinine clearance > 30mL/min: Tirofiban 0.4 mcg/kg/min for 30 minutes, followed by continuous infusion at 0.1 mcg/kg/min - Creatinine clearance < 30mL/min: Tirofiban 0.2 mcg/kg/min for 30 minutes, followed by continuous infusion of 0.05 mcg/kg/min E. Check steady state IIb/IIIa inhibitor verify now assay (>8 hour after initiation) F. Hold Tirofiban 12 hours prior to procedure G. Check IIb/IIIa inhibitor verify now assay (10-12 hours after Tirofiban is discontinued) H. CBC pre and post op I. Reload clopidogrel> 24 hours post op (300 mg X 1 then 75 mg daily) unless prohibitive bleeding risk J. Reduce ASA to pre-procedure dose. Restart ASA, 24 hours port-op if it was D/C prior to procedure K. Check P2Y12 via the Verify Now device post-loading dose of clopidogrel (test cannot be performed w/in 48 hours of the D/C of IIb/IIIa inhibitor (tirofiban)


Inclusion Criteria: - Patients' with BMS/DES on plavix prior to surgery who are in need of an elective procedures Exclusion Criteria: - Patients' with BMS/DES on NOT plavix prior to surgery who are in need of an elective procedures



Primary Contact:

Principal Investigator
Sanjay Kaul, MD
Attending physician

Backup Contact:


Location Contact:

Los Angeles, California 90048
United States

Sanjay Kaul, MD
Phone: 310-423-4876
Email: sanjay.kaul@cshs.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.